Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,746 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lipid Metabolism Clear all
Terminated Phase 2 Interventional Results available

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

NCT04365400
View directory record Official record
Conditions
Hypertriglyceridemia, Type 2 Diabetes
Interventions
DS102, Placebo
Drug
Lead sponsor
Afimmune
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Cerritos, California • Huntington Park, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Not applicable Interventional

Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART

NCT00386971
View directory record Official record
Conditions
Hyperlipidemia, HIV Infections
Interventions
L-carnitine, placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3561774 in Participants With Dyslipidemia

NCT04644809
View directory record Official record
Conditions
Dyslipidemias
Interventions
LY3561774, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
5
States / cities
Cypress, California • Long Beach, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

NCT02410525
View directory record Official record
Conditions
Healthy
Interventions
[11C]PF-06427878, PF-06427878 10 mg, PF-06427878 600 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 10, 2026, 11:02 PM EDT
Enrolling by invitation Not applicable Interventional

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

NCT06834204
View directory record Official record
Conditions
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions
PC2: Primary Care Connect
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 10, 2026, 11:02 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides

NCT00672633
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2013 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms

NCT00701415
View directory record Official record
Conditions
Fabry Disease
Interventions
Agalsidase beta
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
5 Years to 18 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Decatur, Georgia • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Biosynthesis of PGD2 in Vivo

NCT01275300
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Aspirin, Placebo, Niacin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

NCT00630734
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Pravastatin, Darunavir, Ritonavir, Washout
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 10, 2026, 11:02 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Gene Therapy Trial for CLN6 Batten Disease

NCT07582484
View directory record Official record
Conditions
CLN6, Batten Disease, Batten's Disease, Neuronal Ceroid Lipofuscinosis CLN6, Neuronal Ceroid Lipofuscinosis
Interventions
scAAV9.CB.CLN6 (dose: 1.5E14 vector genomes)
Drug
Lead sponsor
The Charlotte and Gwenyth Gray Foundation
Other
Eligibility
4 Months and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phytosterol Supplementation and Cardiovascular Risk

NCT00153738
View directory record Official record
Conditions
Hypercholesteremia
Interventions
phytosterol
Drug
Lead sponsor
The Cooper Institute
Other
Eligibility
20 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 10, 2026, 11:02 PM EDT
Not yet recruiting Not applicable Interventional

Duke Cardiometabolic Prevention Clinic's Impact on High-risk Cardiovascular Patients With Uncontrolled Risk Factors

NCT07117695
View directory record Official record
Conditions
ASCVD, Hyperlipidemia, Hypertension
Interventions
Referral to the Duke Cardiometabolic Prevention Clinic
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 11:02 PM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

NCT01218204
View directory record Official record
Conditions
Dyslipidaemias, Dyslipidemias
Interventions
10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
21
States / cities
Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Not applicable Interventional

Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs

NCT00797407
View directory record Official record
Conditions
Hypercholesterolemia, Aches, Cramps, Weakness
Interventions
Creatine
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Wooster, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2008 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Medication Adherence With Polyglot Meducation

NCT01744392
View directory record Official record
Conditions
Hypertension, Diabetes, Hypercholesterolemia
Interventions
education intervention
Behavioral
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

NCT00439244
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic acid, Placebo, Teriparatide
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 89 Years · Female only
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Sep 10, 2026, 11:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Orchiectomy and Age on Vascular and Metabolic Health in Older Versus Younger Transgender Women

NCT05195164
View directory record Official record
Conditions
Transgender, Gender Identity, Vascular Stiffness, Vascular Inflammation, Insulin Sensitivity, Blood Pressure, Lipid Disorder, Appetitive Behavior
Interventions
No intervention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 10, 2026, 11:02 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Training Effects on Skeletal Muscle Fatty Acid Metabolism

NCT00786487
View directory record Official record
Conditions
Healthy Volunteers
Interventions
20% lipid infusion, glycerol
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

NCT04753606
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions
Obicetrapib
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
19
States / cities
Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Not applicable Interventional

Federal Study of Adherence to Medications in the Elderly (FAME)

NCT00393419
View directory record Official record
Conditions
Medication Adherence, Hypertension, Hyperlipidemia
Interventions
Comprehensive pharmacy care program
Behavioral
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Sep 10, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

NCT01764633
View directory record Official record
Conditions
Dyslipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 85 Years
Enrollment
27,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
326
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 275 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 10, 2026, 11:02 PM EDT